Werewolf Therapeutics has received support from prominent investors in the life science industry and is headed by a skilled team with a demonstrated history of creating new medications for the treatment of cancer. INDUKINE™ molecules are introduced into the body in an inactive state and, upon reaching the tumor microenvironment, are specifically activated to unleash the full biological effectiveness of cytokines and stimulate a potent immune response against tumors. As a result, INDUKINE™ molecules offer the highest therapeutic potential while minimizing undesired effects in non-tumor tissues.